Effectiveness, safety and costs of orphan drugs: an evidence-based review

Onakpoya, Igho J.; Spencer, Elizabeth A.; Thompson, Matthew J.; Heneghan, Carl J.
June 2015
BMJ Open;Jun2015, Vol. 5 Issue 6, p1
Academic Journal
No abstract available.


Related Articles

  • Pricing and reimbursement of orphan drugs: the need for more transparency. Simoens, Steven // Orphanet Journal of Rare Diseases;2011, Vol. 6 Issue 1, p42 

    Pricing and reimbursement of orphan drugs are an issue of high priority for policy makers, legislators, health care professionals, industry leaders, academics and patients. This study aims to conduct a literature review to provide insight into the drivers of orphan drug pricing and...

  • Systematic review of available evidence on 11 high-priced inpatient orphan drugs. Kanters, Tim A.; de Sonneville-Koedoot, Caroline; Redekop, W. Ken; Hakkaart, Leona // Orphanet Journal of Rare Diseases;2013, Vol. 8 Issue 1, p1 

    Background: Attention for Evidence Based Medicine (EBM) is growing, but evidence for orphan drugs is argued to be limited and inferior. This study systematically reviews the available evidence on clinical effectiveness, costeffectiveness and budget impact for orphan drugs. Methods: A systematic...

  • Orphan drugs and the NHS: should we value rarity?  // BMJ: British Medical Journal (International Edition);10/29/2005, Vol. 331 Issue 7523, p1016 

    The article looks at the growing number and costs of drugs for rare diseases are straining healthcare budgets. The author reviews how drugs for rare diseases, known as orphan drugs, are often expensive to produce and, by definition, will only benefit a small number of patients. Current practice...

  • EU evaluation of high-cost orphan drugs urged.  // PharmacoEconomics & Outcomes News;9/1/2012, Issue 661, p2 

    The article focuses on the call by doctors for the European Union (EU) to review the cost effectiveness of orphan drugs for rare hereditary metabolic diseases in relation to a leaked report in The Netherlands on the high annual cost of treatments for Fabry's disease and Pompe's disease.

  • 'Mini' Blockbuster Status of Orphan Drugs Spurs Debate. Serebrov, Mari // BioWorld Insight;4/16/2012, Vol. 20 Issue 16, p1 

    The article presents information on increase in demand of the orphan drugs over the mega blockbuster drugs. It looks at the cost reduction in research and development of drug manufacturing by the incentives provided by the government for development of the orphan drugs. It further mentions the...

  • Orphan Drug Act gets a favourable review.  // PharmacoEconomics & Outcomes News;Feb2015, Vol. 722 Issue 1, p24 

    The article reports on the Orphan Drug Act (ODA) and its review based on cost in the U.S.

  • The Cost-Effectiveness of Orphan Drugs. Weinstein, Milton C. // American Journal of Public Health;Apr91, Vol. 81 Issue 4, p414 

    The author reflects on the cost effectiveness of orphan drugs. He emphasizes that incentives should be encouraged for the use of orphan drugs on the condition that their efficacy in populations be proven. He maintains that clinical trials to prove the levels of efficacy that would justify the...

  • Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. Gammie, Todd; Lu, Christine Y.; Babar, Zaheer Ud-Din // PLoS ONE;10/9/2015, Vol. 10 Issue 10, p1 

    Objective: To review existing regulations and policies utilised by countries to enable patient access to orphan drugs. Methods: A review of the literature (1998 to 2014) was performed to identify relevant, peer-reviewed articles. Using content analysis, we synthesised regulations and policies...

  • Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review. Park, Taehwan; Griggs, Scott; Suh, Dong-Churl // BioDrugs;Aug2015, Vol. 29 Issue 4, p259 

    Background: Monoclonal antibody (mAb)-based orphan drugs have led to advances in the treatment of diseases by selectively targeting molecule functions. However, their high treatment costs impose a substantial cost burden on patients and society. Objectives: The study aimed to systematically...

  • Research & Markets: Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues - 2011 Edition.  // Biomedical Market Newsletter;6/19/2011, p343 

    The article focuses on the report "Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issue 2011 Edition," by Justpharmareport. It states that the report focuses on the orphan drugs use to treat rare diseases in Europe, effect of health technology assessment, and costs of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics